National Institute of Allergy and Infectious Diseases

ADi awarded $2.5M SBIR grant to identify malaria protection biomarkers

Monday, August 13, 2012 10:13 AM

Antigen Discovery (ADi), a biotech based in Irvine, Calif., has received a phase II Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

More... »

SRI International to develop bioadhesive gel for HIV and HSV

Monday, July 30, 2012 10:09 AM

SRI International, a global nonprofit research institute, has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) that will support the development of a topical microbicide gel for combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

More... »

Emergent receives NIAID grant for TB vaccine

Friday, March 23, 2012 01:06 PM

Emergent BioSolutions has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of MVA85A, a candidate vaccine against tuberculosis (TB).

More... »

Soligenix demonstrates proof of concept with vaccine technology

Tuesday, February 7, 2012 10:49 AM

Soligenix, a development-stage biopharmaceutical company, has released results from pre-clinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

More... »

NIH to join multi-center trial of new tuberculosis vaccine

Tuesday, February 7, 2012 07:34 AM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has joined a phase II proof-of-concept clinical trial of a tuberculosis (TB) vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »

Hutchinson Center to lead $20 million HIV research grant

Tuesday, July 12, 2011 12:25 PM

Whether a stem cell transplant using an HIV-infected person’s own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced by the National Institutes of Health to the Fred Hutchinson Cancer Research Center.

More... »